Search research articles
Contact Us
Filters
Showing results (301-310 of 311) with videos related to
Page
of 32
Sort By:
Breast Cancer Research and Treatment
|
June 27, 2007
Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study
Patrick Neven, Robert Paridaens, Gino Pelgrims, et al.
ESMO Open
|
August 28, 2020
Oncological care organisation during COVID-19 outbreak
Concetta Elisa Onesti, Hope S Rugo, Daniele Generali, et al.
Biomedicines
|
July 2, 2021
The NHance<sup>®</sup> Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients
Philippe Aftimos, Christian Rolfo, Sylvie Rottey, et al.
JCO Global Oncology
|
September 8, 2020
Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms
Kamal S Saini, Begoña de Las Heras, Ruth Plummer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2022
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Tae Won Kim, Howard A Burris, Maria J de Miguel Luken, et al.
Cancers
|
September 10, 2021
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer
Francesco Schettini, Mario Giuliano, Matteo Lambertini, et al.
Cancer Treatment Reviews
|
October 6, 2022
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer
Francesco Schettini, Sergio Venturini, Mario Giuliano, et al.
The Lancet. Oncology
|
April 1, 2020
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
José Trigo, Vivek Subbiah, Benjamin Besse, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 23, 2020
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
Vivek Subbiah, Luis Paz-Ares, Benjamin Besse, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 16, 2019
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours
Robin L Jones, Mark J Ratain, Peter J O'Dwyer, et al.
Page
of 32
Search research articles
Search
Showing results (301-310 of 311) with videos related to
Sort By:
Page
of 32
Breast Cancer Research and Treatment
|
June 27, 2007
Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study
Patrick Neven, Robert Paridaens, Gino Pelgrims, et al.
ESMO Open
|
August 28, 2020
Oncological care organisation during COVID-19 outbreak
Concetta Elisa Onesti, Hope S Rugo, Daniele Generali, et al.
Biomedicines
|
July 2, 2021
The NHance<sup>®</sup> Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients
Philippe Aftimos, Christian Rolfo, Sylvie Rottey, et al.
JCO Global Oncology
|
September 8, 2020
Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms
Kamal S Saini, Begoña de Las Heras, Ruth Plummer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2022
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Tae Won Kim, Howard A Burris, Maria J de Miguel Luken, et al.
Cancers
|
September 10, 2021
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer
Francesco Schettini, Mario Giuliano, Matteo Lambertini, et al.
Cancer Treatment Reviews
|
October 6, 2022
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer
Francesco Schettini, Sergio Venturini, Mario Giuliano, et al.
The Lancet. Oncology
|
April 1, 2020
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
José Trigo, Vivek Subbiah, Benjamin Besse, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 23, 2020
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
Vivek Subbiah, Luis Paz-Ares, Benjamin Besse, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 16, 2019
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours
Robin L Jones, Mark J Ratain, Peter J O'Dwyer, et al.
Page
of 32